Ríos, Hernán Andrés
Lövestam-Adrian, Monica
Plainis, Sotiris
Tsilimbaris, Miltiadis
Joussen, Antonia M.
Keegan, David
Charles, Martin
Cunha-Vaz, José
Midena, Edoardo http://orcid.org/0000-0003-3132-6233
Funding for this research was provided by:
Bayer Consumer Health
Università degli Studi di Padova
Article History
Received: 19 December 2022
Revised: 29 September 2023
Accepted: 9 October 2023
First Online: 8 November 2023
Declarations
:
: This article does not contain any studies with human participants or animals performed by any of the authors. Therefore, informed consent was not required for this analysis.
: The Vision Academy is a group of over 100 international experts who, through their collective expertise, provide consensus guidance for managing clinically challenging situations, especially in areas of controversy or with insufficient conclusive evidence. The Vision Academy is funded and facilitated by Bayer. The opinions and guidance of the Vision Academy outputs are those of its members and do not necessarily reflect the opinions of Bayer. Financial arrangements of the authors with companies whose products may be related to the present report are listed below, as declared by the authors:• Hernán Andrés Ríos: no financial interest related to the topic of this manuscript.• Monica Lövestam-Adrian: consultant for Allergan, Bayer, Novartis, Roche, and Santen.• Sotiris Plainis: research funding from Alcon Laboratories, Johnson & Johnson, and Novartis.• Miltiadis Tsilimbaris: personal fees from Allergan, Bayer Hellas, Mavrogenis, and Novartis Hellas; grants from Alcon, Bayer, Johnson & Johnson, and Novartis.• Antonia M. Joussen: personal fees from Allergan, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim, and Novartis; grants from Bayer HealthCare Pharmaceuticals and Novartis.• David Keegan: grant support from Bayer, Novartis, and Samsara Vision; consultant for Samsara Vision.• Martin Charles: consultant for Alcon, Bayer, Novartis, and OcuDyne.• José Cunha-Vaz: Adverum Biotechnologies, Alimera Sciences, Allergan, Bayer, Carl Zeiss Meditec, Gene Signal, Novartis, Oxular, Pfizer, Roche, Sanofi, and Vifor Pharma.• Edoardo Midena: no financial interest related to the topic of this manuscript.